331 related articles for article (PubMed ID: 12063084)
1. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
[TBL] [Abstract][Full Text] [Related]
4. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
5. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
6. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Zhang JY; Kowal DM; Nawoschik SP; Lou Z; Dunlop J
Biochem Pharmacol; 2006 Feb; 71(4):521-9. PubMed ID: 16336943
[TBL] [Abstract][Full Text] [Related]
7. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2008 Nov; 597(1-3):27-33. PubMed ID: 18831971
[TBL] [Abstract][Full Text] [Related]
8. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
[TBL] [Abstract][Full Text] [Related]
11. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
Newman-Tancredi A; Verrièle L; Touzard M; Millan MJ
Eur J Pharmacol; 2001 Oct; 428(2):177-84. PubMed ID: 11675034
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
Newman-Tancredi A; Verrièle L; Millan MJ
Br J Pharmacol; 2001 Jan; 132(2):518-24. PubMed ID: 11159702
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Wood M; Reavill C
Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
[TBL] [Abstract][Full Text] [Related]
15. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.
Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA
Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
[TBL] [Abstract][Full Text] [Related]
17. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells.
Cosi C; Koek W
Eur J Pharmacol; 2001 Dec; 433(1):55-62. PubMed ID: 11755134
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
Marona-Lewicka D; Nichols DE
Psychopharmacology (Berl); 2004 Apr; 172(4):415-21. PubMed ID: 14647959
[TBL] [Abstract][Full Text] [Related]
20. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
